Health care policy expert Jane Halton, AO, PSM, has been picked for her extensive experience in governmental health affairs.
Australia’s Generic Biosimilars Medicines Association (GBMA) has named health policy expert Jane Halton, AO, PSM, to chair the group in its efforts to expand access and affordable care. The GBMA is a trade association of generic and biosimilar medicine suppliers in Australia. Halton replaces Sylvain Vigneault, who has chaired the GBMA for 2 years.
Halton previously served as chair of the Coalition for Epidemic Preparedness Innovations and co-chair of COVAX, the vaccines component of the ACT Accelerator, a global collaboration to speed up the development and production of coronavirus disease 2019 (COVID-19) tests, treatments, and vaccines. She is also a former secretary of the Australian departments of Health and Finance.
In her biography with the Institute for Health Metrics and Evaluation, a global health research center at the University of Washington, Halton is described as having extensive experience with finance, insurance, risk management, information technology, human resources, health and aging, sport, public policy, and international affairs. She is also an adjunct professor at the University of Sydney and the university of Canberra. She has previously served on the executive board of the World Health Organization.
“To return to my domestic health policy roots and lead the GBMA, at such a significantly important time for Australian patients and our vital health care community, is a challenge I am delighted to embrace,” Halton said. “As we look to the arrival of a COVID-19 vaccine for our citizens, we also need to be vigilant that all Australians continue to receive the medicines they need, when they need them.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.